Track Veracyte, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Veracyte, Inc. VCYT · Stock Open Veracyte, Inc. in new tab

24.33 USD
P/E
15.52
EPS
1.54
P/B
1.35
ROE
9.43
Beta
1.96
Target Price
52.10 USD
Veracyte, Inc. logo

Veracyte, Inc.

🧾 Earnings Recap – Q1 2026

Shares surged 23.1% reflecting investor enthusiasm driven by stronger-than-expected volume growth in Decipher tests, advancing clinical catalysts, and improving profitability metrics.

  • Decipher test volume rose 24% year-over-year to approximately 28,000 tests in Q1, driven by expanded provider adoption and higher orders per physician.
  • Growth was particularly strong in high-risk prostate cancer categories, with nearly 30% volume increase in advanced disease segments.
  • Multiple late-stage clinical trials (including GUIDANCE and ENZAMET) advancing, supporting Decipher’s potential as a treatment decision biomarker.
  • Adjusted EBITDA margin exceeded expectations, reflecting ongoing operational efficiency improvements.
  • Upcoming product launches (Prosigna LDT and TrueMRD) represent important growth levers to extend the platform and address new clinical settings.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
P/E15.52
EPS1.54
Book Value17.77
Price to Book1.35
Debt/Equity2.84
% Insiders0.532%
Growth
Revenue Growth0.15%
Earnings Growth0.58%
Estimates
Forward P/E14.41
Forward EPS1.66
Target Mean Price52.10

DCF valuation

Model fair value for Veracyte, Inc. (VCYT)
Result
Sign in to run the valuation for VCYT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Buy · mean target 52.10 USD (low 35.00, high 70.00) · as of 10 Nov 2026
Low 35.00
Mean 52.10
High 70.00
Price 24.33
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Veracyte, Inc. Logo Veracyte, Inc. Analysis (VCYT)

United States Health Care Official Website Stock

Is Veracyte, Inc. a good investment? Veracyte, Inc. (VCYT) is currently trading at 24.33 USD. Market analysts have a consensus price target of 52.10 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 15.52. This valuation is generally in line with the broader market.

Earnings Schedule: Veracyte, Inc. is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 1.66.

Investor FAQ

Does Veracyte, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Veracyte, Inc.?

Veracyte, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of 1.54.

Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) VCYT
FRA (Germany) 12V.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion